Washington, D.C. 20549

                                    Form 10-QSB

(Mark One)

[x]  Quarterly Report under Section 13 or 15(d) of the Securities
     Exchange Act of 1934

     For the quarterly period ended June 30, 2003.
- --------------------------------------------------------------------------

[ ]  Transition Report under Section 13 or 15(d)of the Exchange Act For the
     Transition Period from ________  to  ___________
- --------------------------------------------------------------------------

                     Commission File Number: 000-50095
- --------------------------------------------------------------------------

                  Clinical Trials Assistance Corporation
- --------------------------------------------------------------------------
    (Exact name of small business issuer as specified in its charter)

         Nevada                                  27-0009939
- -------------------------------            ------------------------
(State or other jurisdiction of              (I.R.S. Employer
incorporation or organization)              Identification No.)

     2078 Redwood Crest, Vista, California              92083-7340
   ------------------------------------------         --------------
    (Address of principal executive offices)            (zip code)

Issuer's telephone number:   (760) 727-8448    Fax number:  (760) 598-2611
                             --------------                 --------------

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act of 1934 during the past 12
months (or such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                                          Yes [X]     No [ ]


Check whether the Registrant filed all documents and reports required to
be filed by Section 12, 13 or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.

                                         Yes [ ]     No [ ]


Common Stock, $0.001 par value per share, 20,000,000 shares authorized,
As of June 30, 2003, the issuer had 12,000,000 shares of common
stock outstanding.  Preferred Stock, $0.001 par value per share, 5,000,000
shares authorized, none issued nor outstanding as of June 30, 2003.

Traditional Small Business Disclosure Format (check one)

                                        Yes [  ] No [X]



Item 1.   Financial Statements.................................    3
          Independent Accountant's Report......................    4
          Balance Sheet (unaudited)............................    5
          Statements of Operations (unaudited).................    6
          Statements of Cash Flows (unaudited).................    7
          Notes to Financial Statements........................    8

Item 2.  Management's Discussion and Analysis of Plan
           of Operation........................................    9

Item 3.   Controls and Procedures..............................   13


Item 1.   Legal Proceedings....................................   14

Item 2.   Changes in Securities and Use of Proceeds............   14

Item 3.   Defaults upon Senior Securities......................   14

Item 4.   Submission of Matters to a Vote
           of Security Holders.................................   14

Item 5.   Other Information.....................................  14

Item 6.   Exhibits and Reports on Form 8-K......................  14

Signatures......................................................  15




As prescribed by Item 310 of Regulation S-B, the independent auditor has
reviewed these unaudited interim financial statements of the registrant
for the six months ended .  The financial statements reflect all adjustments
which are, in the opinion of management, necessary to a fair statement of
the results for the interim period presented.  The unaudited financial
statements of registrant for the six months ended, follow.


Beckstead and Watts, LLP
Certified Public Accountants
                                                        3340 Wynn Road, Suite B
                                                            Las Vegas, NV 89102
                                                               702.362.0540 fax


August 9, 2003

Board of Directors
Clinical Trials Assistance Corporation
Las Vegas, NV

We have reviewed the accompanying balance sheet of Clinical Trials Assistance
Corporation (a Nevada corporation) as of June 30, 2003 and the related
statements of operations for the six-month and three-months ended June 30, 2003
and for the period April 22, 2002 (Inception) to June 30, 2002, and statements
of cash flows for the six-months ended June 30, 2003 and for the period April
22, 2002 (Inception) to June 30, 2002.  These financial statements are the
responsibility of the Company's management.

We conducted our reviews in accordance with standards established by the
American Institute of Certified Public Accountants.  A review of interim
financial information consists principally of applying analytical procedures to
financial data, and making inquiries of persons responsible for financial and
accounting matters.  It is substantially less in scope than an audit conducted
in accordance with generally accepted auditing standards, which will be
performed for the full year with the objective of expressing an opinion
regarding the financial statements taken as a whole.  Accordingly, we do not
express such an opinion.

Based on my reviews, we are not aware of any material modifications that should
be made to the accompanying financial statements referred to above for them to
be in conformity with generally accepted accounting principles in the United
States of America.

Beckstead and Watts, LLP


                     Clinical Trials Assistance Corporation
                                Balance Sheet

Balance Sheet

                                                                June 30,

Current assets:
 Cash                                                         $   121,203
                                                              $   121,203

Liabilities and Stockholders' Equity

Current liabilities:
 Accounts payable                                             $    19,908
                                                              $    19,908

Stockholders' equity:
 Preferred stock - Series A, $0.001 par value, 2,000,000
  shares authorized, no shares issued and outstanding                   -
 Preferred stock - Series B, $0.001 par value, 2,000,000
  shares authorized, no shares issued and outstanding                   -
 Preferred stock - Series C, $0.001 par value, 1,000,000
  shares authorized, no shares issued and outstanding                   -
 Common stock - Class A, $0.001 par value, 20,000,000
  shares authorized, 12,000,000 shares issued and outstanding      12,000
 Additional paid-in capital                                        32,600
 Retained earnings (deficit) accumulated during
  development stage                                                56,695
                                                              $   121,203

  The accompanying notes are an integral part of these financial statements.


                    Clinical Trials Assistance Corporation
                            Statement of Operations

Statement of Operations

                  For the Six   April 22, 2002  For the Three  April 22, 2002
                  Months Ended  (Inception) to  Months Ended   (Inception) to
                  ------------  --------------  -------------  --------------
                            June 30,                       June 30,
                  ----------------------------  -----------------------------
                      2003           2002            2003            2002
                  ------------  --------------  -------------  --------------
Revenue           $    130,027  $            -  $     130,027  $            -
Cost of services        29,508               -         29,508               -
                  ------------  --------------  -------------  --------------
                       100,519               -        100,519               -

 General &
  expenses              15,133          11,380         10,976          11,380
                  ------------  --------------  -------------  --------------
                        15,133          11,380         10,976          11,380
                  ------------  --------------  -------------  --------------

Net income (loss) $     85,386  $      (11,380)        89,543  $      (11,380)
                  ============  =============== =============  ===============

Weighted average
 number of common
 shares outstanding-
 basic and fully
 diluted            12,000,000      10,000,000     12,000,000      10,000,000
                  ============  ==============  =============  ==============

Net (loss) per share
 - basic and fully
 diluted          $       0.01  $        (0.00)          0.01  $        (0.00)
                  ============  ==============  =============  ==============

  The accompanying notes are an integral part of these financial statements.


                      Clinical Trials Assistance Corporation
                             Statement of Cash Flows

Statement of Cash Flows

                                                For the Six Months Ended
                                                         June 30,
                                                    2003        2002
                                                -----------  -----------
Cash flows from operating activities
Net income                                           85,386      (11,380)
Adjustments to reconcile net income to net
 cash provided by (used in) operating activities:
 Increase in accounts payable                        19,908            -
                                                -----------  -----------
Net cash (used) by operating activities             105,294      (11,380)
                                                -----------  ------------

Cash flows from financing activities
 Issuances of common stock                                -       15,000
                                                -----------  -----------
Net cash provided by financing activities                 -       15,000
                                                -----------  -----------

Net increase in cash                                105,294        3,620
Cash - beginning                                     15,909            -
                                                -----------  -----------
Cash - ending                                   $   121,203  $     3,620
                                                ===========  ===========
Supplemental disclosures:
   Interest paid                                $         -  $         -
                                                ===========  ===========
   Income taxes paid                            $         -  $         -
                                                ===========  ===========

  The accompanying notes are an integral part of these financial statements.


                    Clinical Trials Assistance Corporation

Note 1 - Basis of Presentation

The consolidated interim financial statements included herein, presented in
accordance with United States generally accepted accounting principles and
stated in US dollars, have been prepared by the Company, without audit,
pursuant to the rules and regulations of the Securities and Exchange
Commission.  Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to such rules and
regulations, although the Company believes that the disclosures are adequate to
make the information presented not misleading.

These statements reflect all adjustments, consisting of normal recurring
adjustments, which, in the opinion of management, are necessary for fair
presentation of the information contained therein.  It is suggested that these
consolidated interim financial statements be read in conjunction with the
financial statements of the Company for the year ended December 31, 2002 and
notes thereto included in the Company's 10-KSB annual report.  The Company
follows the same accounting policies in the preparation of interim reports.

Results of operations for the interim periods are not indicative of annual

Note 2 - Revenue recognition

Clinical Trials Assistance Corporation helps physician researchers recruit
appropriate patients to participate in specific clinical research trials
sponsored by the pharmaceutical industry.  The Company recognizes revenue as it
invoices its customers (physician researchers) on a "completed contract basis"
based on the number of patients it generates to call the research center for an
appointment to participate in a clinical study.  Costs are recognized upon
completion of the of the contracted recruitment campaign in order to match
revenue generated from the campaign.  For the six months ended June 30, 2003,
the Company recognized a total of $130,027 in revenue.

Note 3 - Related party transactions

The Company does not lease or rent any property.  Office services are provided
without charge by a director.  Such costs are immaterial to the financial
statements and, accordingly, have not been reflected therein.  The officers and
directors of the Company are involved in other business activities and may, in
the future, become involved in other business opportunities.  If a specific
business opportunity becomes available, such persons may face a conflict in
selecting between the Company and their other business interests.  The Company
has not formulated a policy for the resolution of such conflicts.



Clinical Trials Assistance Corporation ("CTAC") or ("the Company") is a
development stage company which plans to help physician researchers recruit
appropriate patients to participate in specific clinical research trials
sponsored by the pharmaceutical industry.  In helping the investigative sites
to recruit patients for clinical studies, by developing effective recruitment
programs, which enlist patients to participate in the early stages of these
studies, clinical recruitment companies help the pharmaceutical industry
shorten its development cycles and reduce the cost for evaluating new
pharmaceutical products.  There are no assurances that the Company will be
able to recruit patients faster than its competition.

Clinical Trials Assistance Corporation helps physician researchers find
patients for ongoing clinical studies.  These clinical trials would be
conducted in a physician's office, hospital setting, or private clinic,
who have separately contracted with a major pharmaceutical Company or
U.S. Government agency to test developmental pharmaceutical products,
which have been approved by the Food and Drug Administration ("FDA")
for testing in humans.  In some case, the pharmaceutical companies
themselves conduct clinical research studies.  The Company plans to
solely focus on patient recruitment for these clinical studies.  Said
differently, the Company helps these researchers find patients for
on-going studies.  The researchers screen and evaluate whether these
patients qualify for these studies.  The Company does not plan to
involve itself with data analysis, regulatory services, quality
assurance and other consultation services.  The actual clinical trials
are performed at the investigative sites as approved by the FDA.  The
Company's business is currently focused on the U.S. markets.

In order to accomplish these objectives, the Company established a business
development program with Eugene Boling, MD, a Board Certified Rheumatologist,
located at Boling Clinical Trials ("Boling"), located at 8263 Grove Avenue,
Suite 100, Rancho Cucamonga, CA 91730, who is also a director of the Company.

During the Second Quarter ended June 30, 2003, the Company had the opportunity
to expand its business recruitment activities with other clinical trials centers
throughout the U.S.  Most of the Company's business came through word-of-mouth
referrals from medical centers conducting clinical trials for osteoporosis and
arthritis studies.


Results of Operations

During the Second Quarter ended June 30, 2003, the Company generated $130,027
in revenues.  It is difficult to compare these figures to the same period
last year, since the Company was first incorporated on April 22, 2002.  For
the Quarter ended June 30, 2003, the Company generated $130,027 in revenues
with cost of services of $29,508, general and administrative expenses of
$15,133 with a net income of $85,386.  It should be noted that the Company
incurred additional expenses of $19,908 during the period, which would reduce
net income to $65,478 after these accounts payable have been paid.

The major components to expenses faced by the company in its day to day
operations includes developing databases of potential patients, based on
demographic information, mailing programs and general administrative expenses.
If the Company can maintain its profitability, the company will access salaries,
rent and add additional personnel to the payroll.  Management intends to
continue minimize costs until such a time in its discretion it believes
expansion would be prudent.  One element in making this determination is
positive cash flow on continuous quarterly basis.  If or when the company
is successful in achieving this continuous quarterly positive cash flow, it
is likely that the company will consider expanding its personnel which will
increase costs.

Plan of Operation

Management believes that the Company has enough funds to sustain itself for
The remainder of the calendar year 2003.  Management is still in the process
of developing its business plan in seeking recruitment methodologies to
recruit patients for other disease states than osteoporosis and arthritis.


Liquidity and Capital Resources
- -------------------------------

On April 30, 2002, the Company issued ten million (10,000,000) shares of
its $0.001 par value Common Stock for cash of $10,000, purchased by Mr.
Kamill Rohny, President and founder of the Company.

On September 30, 2002, Clinical Trials completed a private offering of shares
of our common stock pursuant to Regulation D, Rule 504 of the Securities Act of
1933, as amended, and the registration by qualification of said offering in the
State of Nevada, whereby Clinical Trials sold 2,000,000 shares of Common Stock
to approximately 46 unaffiliated shareholders of record, none of whom were or
are officers, directors or affiliates of the Company.

The Company could be required to secure additional financing to fully implement
its entire business plan.  There are no guarantees that such financing will be
available to the Company, or if available, will be on terms and conditions
satisfactory to management.

The Company does not have any preliminary agreements or understandings between
the company and its stockholders/officers and directors with respect to loans
or financing to operate the company.  The Company currently has no arrangements
or commitments for accounts and accounts receivable financing.

The Company has no current commitments or other long-term debt.  Additionally,
the Company has and may in the future invest in short-term investments from
time to time.  There can be no assurance that these investments will result in
profit or loss.


The Company currently has two employees who are also an officers and directors
of the Company.  The Company does not plan to hire any additional employees
until it can become an profitable entity.

The Company has no material commitments for capital expenditures nor does it
foresee the need for such expenditures over the next year.


Market For Company's Common Stock

Market Information

The common stock of the Company is not traded on the NASDAQ OTC Bulletin
Board or any other formal or national securities exchange.  There is no
trading market for the Company's Common Stock at present and there has
been no trading market to date.  The Company has applied for listing of
its common stock on the Over the Counter Bulletin Board.  At the time of
this filing, the Company is still in the review process with the NASD.

There is currently no common stock which is subject to outstanding
options or warrants to purchase, or securities convertible into, the
Company's common stock.


Holders of common stock are entitled to receive such dividends as the board of
directors may from time to time declare out of funds legally  available for the
payment of dividends. No dividends have been paid on our common stock, and we
do not anticipate paying any dividends on our common stock in the foreseeable

Forward-Looking Statements

This Form 10-QSB includes "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended.  All statements, other than
statements of historical facts, included or incorporated by reference in this
Form 10-QSB which address activities, events or developments which the Company
expects or anticipates will or may occur in the future, including such things
as future capital expenditures (including the amount and nature thereof),
finding suitable merger or acquisition candidates, expansion and growth of the
Company's business and operations, and other such matters are forward-looking
statements.  These statements are based on certain assumptions and analyses
made by the Company in light of its experience and its perception of
historical trends, current conditions and expected future developments as
well as other factors it believes are appropriate in the circumstances.

However, whether actual results or developments will conform with the
Company's expectations and predictions is subject to a number of risks and
uncertainties, general economic  market and business conditions; the business
opportunities (or lack thereof) that may be presented to and pursued by the
Company; changes in laws or regulation; and other factors, most of which
are beyond the control of the Company.


This Form10-QSB contains statements that constitute "forward-looking
statements." These forward-looking statements can be identified by the use of
predictive, future-tense or forward-looking terminology, such as "believes,"
"anticipates," "expects," "estimates," "plans," "may," "will," or similar
terms. These statements appear in a number of places in this Registration and
include statements regarding the intent, belief or current expectations of
the Company, its directors or its officers with respect to, among other
things: (i) trends affecting the Company's financial condition or results of
operations for its limited history; (ii) the Company's business and growth
strategies; and, (iii) the Company's financing plans.  Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve significant risks and uncertainties, and that actual
results may differ materially from those projected in the forward-looking
statements as a result of various factors.  Factors that could adversely
affect actual results and performance include, among others, the Company's
limited operating history, dependence on continued growth in the irrigation
industry, potential fluctuations in quarterly operating results and expenses,
government regulation dealing with irrigation systems, technological change
and competition.

Consequently, all of the forward-looking statements made in this Form 10-QSB
are qualified by these cautionary statements and there can be no assurance
that the actual results or developments anticipated by the Company will be
realized or, even if substantially realized, that they will have the expected
consequence to or effects on the Company or its business or operations.  The
Company assumes no obligations to update any such forward-looking statements.

Item 3. Controls and Procedures

Within the 90 days prior to the date of this report, we carried out an
evaluation, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls
and procedures pursuant to Securities Exchange Act Rule 13a-14. Based upon
that evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures are effective in timely
alerting them to material information relating to us (including our
consolidated subsidiaries) required to be included in our periodic SEC filings.
There have been no significant changes in our internal controls or in other
factors that could significantly affect internal controls subsequent to the
date of their evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.


                       PART II OTHER INFORMATION

ITEM 1.  Legal Proceedings

The Company is not a party to any legal proceedings.

ITEM 2.  Changes in Securities and Use of Proceeds


ITEM 3.  Defaults upon Senior Securities


ITEM 4.  Submission of Matters to a Vote of Security Holders

During the quarter ended, no matters were submitted to the Company's
security holders.

ITEM 5.  Other Information


ITEM 6.  Exhibits and Reports on Form 8-K

(a)  Exhibits

  Number        Title of Document
     99     Certification Pursuant to Title 18, United States
            Code, Section 1350, as Adopted Pursuant to Section 906
            of The Sarbanes-Oxley Act Of 2002

(b)  Reports on Form 8-K

The Company did not file any Current Reports on Form 8-K for the Quarter ended
June 30, 2003.



In accordance with Section 12 of the Securities Exchange Act of 1934, the
registrant caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized.

                          Clinical Trials Assistance Corporation

Dated:  August 13, 2003    By:  /s/ Kamill Rohny
                                    Kamill Rohny
                                    Chief Executive Officer
                                    Chief Financial Officer



In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

                                   CLINICAL TRIALS ASSISTANCE CORPORATION

Date: August 13, 2003                      By: /s/ Kamill Rohny
                                                   Kamill Rohny
                                                   Chief Executive Officer



I, Kamill Rohny, certify that:

     1.   I  have  reviewed  this quarterly  report  on  Form 10-QSB of Clinical
          Trials Assistance Corporation;

     2.   Based on my  knowledge,  this  quarterly  report  does not contain any
          untrue  statement of a material  fact or omit to state a material fact
          necessary to make the statements  made, in light of the  circumstances
          under which such  statements were made, not misleading with respect to
          the period covered by this quarterly report;

     3.   Based on my knowledge,  the financial statements,  and other financial
          information  included in this quarterly report,  fairly present in all
          material respects the financial  condition,  results of operations and
          cash flows of the registrant as of, and for, the periods  presented in
          this quarterly report;

     4.   The registrant's  other certifying  officers and I are responsible for
          establishing  and maintaining  disclosure  controls and procedures (as
          defined in Exchange  Act Rules 13a-15(e) and 15d-15(e)) for the
          registrant and have:

          a)   Designed such disclosure controls and procedures, or caused such
               disclosure controls and procedures to be designed under our
               supervision, to ensure that material information relating to the
               registrant, including its consolidated subsidiaries, is made
               known to us by others within those entities, particularly during
               the period in which this report is being prepared;

          b)   evaluated  the  effectiveness  of  the  registrant's   disclosure
               controls and  procedures and presented in this quarterly report
               our conclusions about the effectiveness of the disclosure
               controls and procedures, as of the end of the  period covered by
               this report based on such evaluation; and

          c)   Disclosed in this report any change in the registrant's internal
               control over financial reporting that occurred during the
               registrant's most recent fiscal quarter (the registrant's fourth
               fiscal quarter in the case of an annual report) that has
               materially affected, or is reasonably likely to materially
               affect, the registrant's internal control over financial
               reporting; and

     5.   The registrant's other certifying officer(s) and I have disclosed,
          based on our most recent evaluation of internal control over financial
          reporting, to the registrant's auditors and to the audit committee of
          the registrant's board of directors (or persons fulfilling the
          equivalent function):

          a)   All significant deficiencies and material weaknesses in the
               design or operation of internal control over financial reporting
               which are reasonably likely to adversely affect the registrant's
               ability to record, process, summarize and report financial
               information; and

          b)   any fraud, whether or not material, that  involves  management or
               other employees who have a  significant role in the  registrant's
               internal control over financial reporting.

August 13, 2003                             /s/ Kamill Rohny
---------------                            ---------------------------
                                             Kamill Rohny
                                             Chief Executive Officer
                                             Chief Financial Officer